Aldeyra Therapeutics (137) Price & Analysis

0 Followers

137 Stock Chart & Stats

€1.52

-€0.11(-2.29%)

At close: Jan 08 4:00 PM EST

€1.52

-€0.11(-2.29%)

Day’s Range― - ―

52-Week Range€1.05 - €5.05

Previous CloseN/A

Volume0.00

Average Volume (3M)135.00

Market Cap

€90.07M

Enterprise Value€52.45

Total Cash (Recent Filing)€65.00M

Total Debt (Recent Filing)€15.51M

Price to Earnings (P/E)―

Beta2.71

Next Earnings

Jul 31, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding60,321,068

10 Day Avg. Volume185

30 Day Avg. Volume135

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)7.03

Price to Sales (P/S)0.00

P/FCF Ratio-9.33

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.76

Price Target Upside15.57% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)-0.26

Revenue Forecast (FY)€1.10M

Bulls Say, Bears Say

Bulls Say

Extended Cash RunwayA disclosed cash runway to 2028 materially reduces near-term financing pressure and gives management time to complete pivotal trials and FDA interactions. This runway supports execution of clinical programs and lowers near-term dilution risk, strengthening mid-term operational visibility.

Platform & Diversified PipelineA mechanistic RASP-modulation platform across multiple therapeutic areas provides multiple development paths and ‘shots on goal.’ This structural diversification reduces dependence on a single indication, increasing long-term upside if one program succeeds while others progress.

Governance StrengthenedAppointment of an independent audit committee chair and compliant governance bolsters financial oversight and audit credibility. Stronger governance improves investor and regulator confidence and supports disciplined reporting and risk management over the medium term.

Bears Say

No Revenue; Persistent LossesThe company has no commercial revenue and reports recurring sizable net losses, reflecting lack of product commercialization. Sustained losses erode equity, force reliance on capital markets, and make future value creation contingent on successful trial outcomes and approvals.

Cash Flow Volatility & Sustainability RiskHistoric negative operating and free cash flows indicate structural cash burn to fund trials. The recent TTM improvement is an unusual swing and may not be durable, leaving the company exposed to financing needs and execution risk if cash generation does not remain positive.

Limited Operational ScaleAn extremely small headcount limits internal capacity to run simultaneous late-stage programs, scale clinical operations, and prepare commercialization. This increases reliance on external partners or hires, raising execution and timing risk over the next several quarters.

Aldeyra Therapeutics News

Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support

The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). On June 9, 2026, following its annual...

1M ago

ALDX

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims

A class action lawsuit was filed against Aldeyra Therapeutics ($ALDX) on March 30, 2026. Plaintiffs in the federal...

2M ago

ALDX

Aldeyra Updates Reproxalap Outlook and Extends Cash Runway

The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). On May 1, 2026, Aldeyra Therapeutics released...

3M ago

ALDX

Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures

Aldeyra (ALDX) said its dry eye drug reproxalap had demonstrated broad-based, rapid-onset activity, consistent safety, and statistically significant, clinically relevant activity across Phase...

3M ago

ALDX

Aldeyra Therapeutics Announces Upcoming Board Member Departure

Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On April 20, 2026, Aldeyra Therapeutics, Inc. announced that...

3M ago

ALDX

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky

NEW YORK, April 17, 2026 — Institutional investors holding positions in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) during the...

3M ago

ALDX

Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data

Aldeyra Therapeutics ($ALDX) told investors its dry eye drug reproxalap was showing strong, consistent results across multiple late-stage...

4M ago

ALDX

Aldeyra Repays Hercules Loan, Boosting Financial Flexibility

The latest update is out from Aldeyra Therapeutics ( ($ALDX) ). Aldeyra Therapeutics, Inc. previously entered into a...

4M ago

ALDX

Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds

H.C. Wainwright analyst Matthew Caufield maintained a Hold rating on Aldeyra Therapeutics today and set a price target...

4M ago

ALDX

Aldeyra downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2,...

4M ago

ALDX

Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!

Traders will find the top stock market stories for Tuesday in our daily wrap-up. ...

4M ago

FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy

Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug...

4M ago

ALDX

Aldeyra options imply 10.9% move in share price post-earnings

Pre-earnings options volume in Aldeyra (ALDX) is 1.6x normal with puts leading calls 10:9. Implied volatility suggests the...

5M ago

ALDX

Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup

The major averages were broadly lower near noon as traders eyed a key jobs report and additional economic...

7M ago

137 FAQ

What was Aldeyra Therapeutics’s price range in the past 12 months?

Aldeyra Therapeutics lowest stock price was €1.05 and its highest was €5.05 in the past 12 months.

What is Aldeyra Therapeutics’s market cap?

Aldeyra Therapeutics’s market cap is €90.07M.

When is Aldeyra Therapeutics’s upcoming earnings report date?

Aldeyra Therapeutics’s upcoming earnings report date is Jul 31, 2026 which is in 7 days.

How were Aldeyra Therapeutics’s earnings last quarter?

Aldeyra Therapeutics released its earnings results on May 07, 2026. The company reported -€0.053 earnings per share for the quarter, beating the consensus estimate of -€0.086 by €0.033.

Is Aldeyra Therapeutics overvalued?

According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aldeyra Therapeutics pay dividends?

Aldeyra Therapeutics does not currently pay dividends.

What is Aldeyra Therapeutics’s EPS estimate?

Aldeyra Therapeutics’s EPS estimate is -0.07.

How many shares outstanding does Aldeyra Therapeutics have?

Aldeyra Therapeutics has 60,321,068 shares outstanding.

What happened to Aldeyra Therapeutics’s price movement after its last earnings report?

Aldeyra Therapeutics reported an EPS of -€0.053 in its last earnings report, beating expectations of -€0.086. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Aldeyra Therapeutics?

Currently, no hedge funds are holding shares in DE:137

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aldeyra Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-28.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics (137) Earnings & Revenues

Historic Earnings Reports

137 Stock 12 Month Forecast

Average Price Target

€1.76

▲(15.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","5":"€5","1.25":"€1.25","2.5":"€2.5","3.75":"€3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.7566033,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7566033,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7566033,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.0735848692307695,2.0471697384615384,2.0207546076923077,1.9943394769230771,1.9679243461538463,1.9415092153846154,1.9150940846153848,1.888678953846154,1.862263823076923,1.8358486923076924,1.8094335615384616,1.783018430769231,{"y":1.7566033,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.0735848692307695,2.0471697384615384,2.0207546076923077,1.9943394769230771,1.9679243461538463,1.9415092153846154,1.9150940846153848,1.888678953846154,1.862263823076923,1.8358486923076924,1.8094335615384616,1.783018430769231,{"y":1.7566033,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,2.0735848692307695,2.0471697384615384,2.0207546076923077,1.9943394769230771,1.9679243461538463,1.9415092153846154,1.9150940846153848,1.888678953846154,1.862263823076923,1.8358486923076924,1.8094335615384616,1.783018430769231,{"y":1.7566033,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.199,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.052,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.906,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.446,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.366,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.459,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.321,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.561,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.777,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.444,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >